RhumbLine Advisers’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-57,747
| Closed | -$1.04M | – | 2844 |
|
|
2017
Q4 | $1.04M | Buy |
57,747
+7,397
| +15% | +$91.1K | ﹤0.01% | 1929 |
|
|
2017
Q3 | $594K | Buy |
50,350
+1,540
| +3% | +$17.3K | ﹤0.01% | 2227 |
|
|
2017
Q2 | $513K | Buy |
48,810
+423
| +0.9% | +$4.31K | ﹤0.01% | 2280 |
|
|
2017
Q1 | $532K | Buy |
48,387
+19,737
| +69% | +$229K | ﹤0.01% | 2216 |
|
|
2016
Q4 | $388K | Buy |
28,650
+1,295
| +5% | +$18.1K | ﹤0.01% | 2357 |
|
|
2016
Q3 | $337K | Buy |
27,355
+425
| +2% | +$5.01K | ﹤0.01% | 2418 |
|
|
2016
Q2 | $295K | Buy |
26,930
+580
| +2% | +$6.49K | ﹤0.01% | 2547 |
|
|
2016
Q1 | $288K | Buy |
26,350
+170
| +0.6% | +$2.15K | ﹤0.01% | 2548 |
|
|
2015
Q4 | $453K | Buy |
26,180
+3,175
| +14% | +$56.9K | ﹤0.01% | 2305 |
|
|
2015
Q3 | $457K | Buy |
23,005
+922
| +4% | +$21.1K | ﹤0.01% | 2287 |
|
|
2015
Q2 | $363K | Buy |
22,083
+4,570
| +26% | +$79.2K | ﹤0.01% | 2528 |
|
|
2015
Q1 | $273K | Buy |
17,513
+2,780
| +19% | +$43.1K | ﹤0.01% | 2666 |
|
|
2014
Q4 | $210K | Buy |
14,733
+325
| +2% | +$3.43K | ﹤0.01% | 2792 |
|
|
2014
Q3 | $94K | Hold |
14,408
| – | – | ﹤0.01% | 2934 |
|
|
2014
Q2 | $99K | Buy |
14,408
+1,527
| +12% | +$10.8K | ﹤0.01% | 2971 |
|
|
2014
Q1 | $92K | Sell |
12,881
-660
| -5% | -$5.65K | ﹤0.01% | 2931 |
|
|
2013
Q4 | $127K | Hold |
13,541
| – | – | ﹤0.01% | 2938 |
|
|
2013
Q3 | $84K | Sell |
13,541
-144
| -1% | -$899 | ﹤0.01% | 2947 |
|
|
2013
Q2 | $90K | Buy |
+13,685
| New | +$109K | ﹤0.01% | 3258 |
|
Other funds holding SCMP
RhumbLine Advisers's SCMP Position: Q1 2018 in Review
RhumbLine Advisers sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 57,747 shares — an estimated $1.04M sold.
RhumbLine Advisers first reported a position in SCMP in Q2 2013 and held it in 19 quarters. The position peaked at $1.04M in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.
- RhumbLine Advisers reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
- RhumbLine Advisers sold 57,747 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.04M.
- RhumbLine Advisers first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 19 quarters.
- RhumbLine Advisers's Sucampo Pharmaceuticals, Inc. position peaked at $1.04M in Q4 2017.
- 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.
Based on RhumbLine Advisers's 13F filing for Q1 2018, filed 2 May 2018.